(Q45185323)

10 December 2017

title

Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression (English)

1 reference

10 December 2017

1 reference

1

Celestia Higano

1 reference

10 December 2017

Andrew Shields

2

1 reference

10 December 2017

Nathanael Wood

series ordinal

3

1 reference

10 December 2017

Judy Brown

series ordinal

4

1 reference

10 December 2017

Cathy Tangen

series ordinal

5

1 reference

10 December 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

10 December 2017

1 reference

10 December 2017

volume

64

1 reference

10 December 2017

issue

6

1 reference

10 December 2017

page(s)

1182-1186

1 reference

Natural history of progression after PSA elevation following radical prostatectomy

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.019

Hip fracture prediction in elderly men and women: validation in the Rotterdam study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.019

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.019

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.019

Risk factors for spinal osteoporosis in men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.019

Osteoporosis and decline of gonadal function in the elderly male

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.019

Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.019

The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.019

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.019

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.019

Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.019

TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.019

Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.019

Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.019

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.019

10.1016/J.UROLOGY.2004.07.019

7 January 2021

Identifiers

DOI

1 reference

10 December 2017

1 reference